HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

People In Brief

This article was originally published in The Tan Sheet

Executive Summary

Himmel named ChromaDex CEO; Pinney reorganizes senior management; FDA vet Chappell jumps to Greenleaf; more People In Brief.

You may also be interested in...



People In Brief

HPM partner McNamara dies: Stephen H. McNamara, a partner in the Hyman, Phelps & McNamara law firm and a congressional advisor on the Dietary Supplement Health and Education Act, died Dec. 28 of complications from cancer at the age of 66. McNamara's wife Caroline, children Matthew and Deborah and six grandchildren survive him. He was a member of HPM from 1984 until poor health forced his withdrawal from practice in 2003. He advised Congress in the development of DSHEA, which passed in 1994. Prior to joining HPM, McNamara was senior vice president and general counsel for the Cosmetic, Toiletry and Fragrance Association (now the Personal Care Products Council). He also was a staff attorney at FDA, a senior trial attorney and the associate chief counsel for food. He served as acting chief counsel for about a year and was twice given the FDA Award of Merit, the agency's highest service award. McNamara served as a chaplain's assistant in the U.S. Army from 1967-1969, and was awarded the Bronze Star, the Purple Heart and the Army Commendation Medal

US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising

US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”

Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa

The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

RS124712

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel